Drug
Xeruborbactam clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2024
How studies write it
Studies that test it under each name
Name
- Xeruborbactam
- 1
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Beta-Lactamase Inhibitors source
Studies
Open first, then newest update. How each study uses xeruborbactam is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal ImpairmentCompletedPhase 1Qpex Biopharma, Inc.NCT07104162Written as Cefiderocol/Xeruborbactam
- A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult ParticipantsCompletedPhase 1Qpex Biopharma, Inc.NCT06547554Written as Xeruborbactam
- Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male ParticipantsCompletedPhase 1Qpex Biopharma, Inc.NCT07083817Written as [14C]Xeruborbactam
Codes
What other systems call xeruborbactam · ClinicalTrials.gg INT016324
- UNII (FDA) DE79L822UYXERUBORBACTAMOne source FDA
- NCI Thesaurus C184848XeruborbactamOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DE79L822UY | XERUBORBACTAM | One source FDA |
| NCI Thesaurus | C184848 | Xeruborbactam | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.